eden

Innovations that work.™

Annual Report

for the Year Ended 30 June 2019

CONTENTS

HIGHLIGHTS DURING THE 2018-2019 FINANCIAL YEAR

SALES

	Sales for year ended 30 Jun 2019, A$000's	Sales for year ended 30 Jun 2018, A$000's	Sales % Change
EdenCrete®	1,615	712	+127%
OptiBlend®	720	606	+19%
Total	2,335	1,318	+77%

EDENCRETE®

- Sales increased by 127% compared to the prior year, exceeding $1.5 million.

Georgia

- First Federal funded Georgia Department of Transportation (GDOT) highway repair project using EdenCrete® undertaken using US$722,000 worth of EdenCrete® in total.
- EdenCrete® successfully completed 12 months' field trail for GDOT new concrete pavement.
- MARTA Whitepaper issued detailing the excellent performance of EdenCrete® over a 2 year field trial commencing in 2016 – highly encouraging conclusions endorsing use of EdenCrete®.
- Next Federal funded GDOT repair project was advertised for tenders and included specifications suitable for use of EdenCrete®.

Colorado

- Increasing commercial and residential sales emerged for use in concrete slabs, driveways, walls, and shotcrete and grout; repeat orders from six Colorado customers.
- Denver Public Works specified by name, the addition of EdenCrete® in a contract for concrete for first time in Colorado.

New York

- Following successful truck trials of EdenCrete®Pz with a significant New York based ready mix operator, certification testing of two high strength concrete mix designs for high rise construction was successfully undertaken by an independent laboratory that provides engineering-based certification of the designs.
- The certification of the high-performing concrete mix designs allows for use in commercial concrete production in the huge New York concrete market.

Texas

- Two more cost effective EdenCrete® concrete mix designs for use in prestressed highway bridge beams were successfully developed.
- Approval of these mix designs by Texas Department of Transportation (TXDOT) proposed to be undertaken, which may result in a resumption of the regular sales of EdenCrete® in Texas.

NTPEP Evaluations of EdenCrete® and EdenCrete® Pz

- NTPEP evaluations, over 12 months, of both EdenCrete® and EdenCrete® Pz, were finally completed in July 2019, opening possibility of approvals of both products by all US DOTs.

AUSTRALIA AND NEW ZEALAND

- Parchem appointed Australian and New Zealand EdenCrete® distributor and the first Australian commercial trials were held in April 2019.

KOREA

- Highly encouraging trial results achieved in Korean university trials of EdenCrete® HC and EdenCrete®Pz in two different concrete mixes (for concrete pavement and for precast concrete applications) tested for overall durability by analysing a wide range of performance characteristics.

INDIA

- EdenCrete® Indian marketing launched.
- Successful initial Indian trials of EdenCrete® produced very encouraging results confirming earlier US laboratory conclusions.
- Trials have since commenced with a number of large Indian companies involved in ready mix industry or construction.

EUROPE

- Successful trials of EdenCrete® with two European companies (one a large multinational construction company) - discussions and trials are continuing with both.

OptiBlend®

- Sales worth A$722,000 were invoiced during the year, including sales in India for five units to Bosch worth a total of A$169,000.

EdenPlast™

- The ARC funded research project with University of Queensland continued focusing on moving the production of master batches of CNT enriched plastics towards commercialisation.
- A second patent application was lodged.

Hydrogen

- Eden's hydrogen production technology was reviewed in joint laboratory trials undertaken with a large multinational chemical company.

CORPORATE DIRECTORY

DIRECTORS:

Gregory H Solomon LLB (Executive Chairman)
Douglas H Solomon BJuris LLB (Hons) (Non-Executive)
Lazaros Nikeas B.A. (Non-Executive)
Stephen D Dunmead B.Sc., M.Sc., Ph.D. (Non-Executive)

COMPANY SECRETARY:

Aaron P Gates BCom CA AGIA

REGISTERED OFFICE:

Level 15
197 St Georges Terrace
Perth
Western Australia 6000
Tel +61 8 9282 5889
Fax +61 8 9282 5866
Email: mailroom@edeninnovations.com.au
Website: www.edeninnovations.com

SOLICITORS:

Solomon Brothers
Level 15
197 St Georges Terrace
Perth WA 6000

AUDITORS:

Nexia Perth Audit Services Pty Ltd
Level 3
88 William Street
Perth WA 6000

SHARE REGISTRY:

Advanced Share Registry Services
110 Stirling Highway
Nedlands WA 6009

STOCK EXCHANGE LISTING:

ASX Code: EDE (ordinary shares) **EDEOB** (8 cent options)

Quotation has been granted for all the ordinary shares and issued EDEOB options of the company on all Member Exchanges of the Australian Securities Exchange Limited.

REVIEW OF OPERATIONS

EDENCRETE® (Eden 100%)

During the year, total EdenCrete® sales (A$1,615,000) increased significantly as compared to the prior year (A$712,000), increasing 127%.

Details of the overall progress made during the year are detailed below.

GEORGIA INFRASTRUCTURE

The value of EdenCrete® used in all completed Georgia Department of Transportation (GDOT) contracts over past 2 years has reached US$1.26 million, with a further US$610,000 possible in 2019-20. The 2019-20 GDOT funded highway repair projects that are currently planned (but can change during the year) would require approximately US$353,000 worth of EdenCrete® and the forthcoming GDOT/Federal Highway Administration (FHWA) funded contract is currently estimated at US$257,000.

Various trials and high-level discussions with government and industry are in progress in Georgia related to a wide range of possible new projects.

First Federally Funded GDOT Repair Project - Interstate Highway I-16 Twiggs County

Following an increase in the scope of this project, which originally was limited to carrying out major repairs along a particularly troublesome 10 mile long section of the Interstate Federal Highway I-16, which were estimated to require approximately US$525,000 worth of EdenCrete®, the expanded project used US$721,000 worth of EdenCrete®.

During the year five tanker loads of EdenCrete® and two smaller subsequent shipments were sent to Georgia for this project, resulting in an aggregate of approximately 27,700 US gallons (104,855 litres) of EdenCrete® being delivered for this project.

This project is the first joint GDOT/FHWA project in which EdenCrete® was used. The tender specifications for this project included a number of additional performance requirements for the concrete, all of which EdenCrete® had previously met. Testing of the EdenCrete® enriched concrete used on this project was undertaken and confirmed that the addition of EdenCrete® resulted in the concrete exceeding these additional performance requirements.

Whilst EdenCrete® was not named in the tender specifications for this Federal project (although it is named in the standard specifications for State funded highway repair projects in Georgia), the addition of EdenCrete® is considered likely to be the most, or one of the most, cost effective methods for the contractors to meet all of these additional performance requirements.

For this modest increase in costs, based upon the observed performance of EdenCrete® in highway and pavement field trials in Georgia over the past three and a half years, a very significant increase (and perhaps even a doubling) in the service life of the concrete is anticipated, resulting in a very compelling economic case for EdenCrete® to be added to the concrete.

Next Federal /GDOT Funded Highway Repair Project - Cobb/Fulton Counties

During the year, the contract was awarded for this large project that will involve repairs along 17.35 miles of Interstate Highway I-285/SR 407 (in Fulton and Cobb counties).

Eden has been advised by the ready mix supplier selected by the successful tenderer to the project that the work on this project is scheduled to commence around September 2019, and that EdenCrete® is intended to be used. Based on the original scope of work, the project will require EdenCrete® of an approximate estimated value of US$257,000, but the scope of this contract could well increase in the same way that the scope of the first Federal funded repair project was increased.

GDOT - Repair Projects – Year Ending 30 June 2019

During the year, three GDOT State funded repair projects were completed, using in aggregate US$115,000 worth of EdenCrete®.

GDOT - Successful Completion of Field Trial for Use in New Concrete Pavements

During the year, EdenCrete® successfully completed a 12 months field trial for use in new concrete pavements that was previously announced (see Eden ASX announcements - EDE: ASX 30 March 2017 and EDE: ASX 4 May 2018). Eden proposes to now request GDOT to add EdenCrete® to its approved products list for use in new concrete pavements.

Metropolitan Atlanta Rapid Transit Authority (MARTA)

A MARTA Whitepaper prepared jointly by engineers from both MARTA and Eden that evaluated the performance, over 2 years, of EdenCrete® in a field trial that commenced in May 2016 at MARTA's Brady Mobility Centre, was prepared and signed off by the parties in October 2018.

The Whitepaper included very positive conclusions endorsing use of EdenCrete® and was released to the public after signing (see announcement ASX: EDE 18 October 2018).

The conclusions from the MARTA Whitepaper were:

"The results of lab testing indicate the inclusion of EdenCrete® will provide a significant extension of service life to the concrete. MARTA's use of EdenCrete® is anticipated to extend the service life and reduce the frequency of maintenance projects to keep the parking areas in service. Progressive site visits over the course of 2 years in-service show the EdenCrete® sections outperforming the adjacent sections of standard concrete. The surface of the reference is abrading significantly more irregularly, and rapidly, than the surface of the slabs containing EdenCrete®.

Over time, the reduced maintenance schedule and longer service life before needing replacement will outweigh any upfront cost of EdenCrete®. Testing also indicates that dosages of EdenCrete® below 3 gal./yd.3 of concrete (used in the Brady evaluation) will perform successfully in a similar environment. Lower dosages of EdenCrete® around 1.0 to 1.5 gal./yd.3 are anticipated to perform successfully for MARTA, while providing a savings beyond that which was trialled at the Brady facility in 2016.

MARTA chose to undertake this evaluation based on the success GDOT has had with EdenCrete® to date. According to David Springstead, responsible for MARTA AGM Capital Programs & Development:

"With GDOT's specification of EdenCrete in mix design, MARTA will look to incorporate EdenCrete in both design criteria and specifications as a viable value-added option."

The implementation of EdenCrete® into projects or applications deemed appropriate by MARTA will provide savings by reducing the life cycle cost of the concrete and reducing the frequency of disruptive maintenance projects which affect both operations and the revenue stream.

Transit departments across the nation are encouraged to contact MARTA and Eden Innovations personnel listed below with any questions regarding the use of EdenCrete® and how it can improve concrete applications across the spectrum of use."

Discussions between Eden personnel and senior MARTA engineers concerning specifications and possible future projects for EdenCrete®, have commenced, and are hoped will lead to EdenCrete® being used in suitable future MARTA projects.

Georgia Commercial EdenCrete® Sales

Three industrial flooring projects in Georgia were completed during the year and several further similar industrial projects are presently being planned or discussed with different customers.

COLORADO

Significant year on year growth of EdenCrete® usage and sales in Colorado

Usage and sales of EdenCrete® products in Colorado continued its rise, resulting in the following impressive year on year increases in sales of EdenCrete® products in Colorado:

- The number of regional ready mix operators using it on a regular basis increased 500% from 1 to 6.
- The number of regional contractors using it on a regular basis including for slabs and driveways increased 400% from 2 to 10.
- The number of regional contractors using it on a regular basis for variety of shotcrete applications increased 800% from 1 to 9.
- The aggregate year on year EdenCrete® sales revenue in Colorado increased 220%.

Colorado - EdenCrete® used in first shotcrete application for CDOT

Following approval by the Colorado Department of Transportation ("CDOT") for EdenCrete® to be used in a shotcrete concrete mix, during the year EdenCrete® was used for the first time on the CDOT Central 70 project in Denver (see Figure 1).

Figure 1. EdenCrete® shotcrete concrete mix being applied

REVIEW OF OPERATIONS (Continued)

This project which is ongoing, involves the reconstruction of 10 miles of the I-70 Interstate Highway, including sinking part of the highway and the establishment of a park above it (as detailed in Eden's 30 September 2018 Quarterly Activities Report - ASX:EDE 29 October 2018).

The EdenCrete® shotcrete mix was used to stabilize a buttress wall under an I-70 bridge and performed very well. The total project is estimated to require 6,000-10,000 cu/yards of shotcrete. EdenCrete® is currently being added at 0.5 gallons/ cu. yard of concrete.

This project is very important for several reasons. It is:

- the first contract for the use of EdenCrete® in a shotcrete application;
- the first time EdenCrete® has been approved by any Department of Transportation for a shotcrete application; and
- the largest contract, to date, for EdenCrete® on a CDOT project.

It also represents a further major milestone for EdenCrete® as it continues to expand its sales footprint into the huge U.S. infrastructure and commercial concrete markets.

Additionally, this project has great relevance for the potential of EdenCrete® in shotcrete applications both in the USA and other parts of the world, with many significant tunnel projects being planned or being constructed. This includes South Korea and Australia, both of which EdenCrete® is intended to be marketed.

Colorado Independent Case Study

An independent case study by members of the Department of Civil Engineering, University of Denver, Colorado, was published on some of the benefits delivered by EdenCrete® enriched concrete used in field trials being conducted by the Denver Public Works (see Figure 2) to evaluate the performance of EdenCrete® when concrete is exposed to heavy dosages of de-icing salts and road chemicals (see Eden's ASX Announcement ASX: EDE 20 February 2017).

The case study is available at: http://edeninnovations.com/newsandmedia/#corporate-news

The study provides a strong, independent assessment of the significant benefits delivered by EdenCrete® in this field trial. It analysed the comparative performance of a standard concrete mix, and two other similar mixes but with EdenCrete® added at 2 gallons/ cubic yard of concrete and at 3 gallons/ cubic yard of concrete respectively. It measured and compared changes in the three mixes in respect to compressive strength at 7 days and 28 days, as well as slump that was measured at the time of conducting the tests.

In all the tests, the EdenCrete® enriched concrete outperformed the standard concrete mix.

Of relevance is that the initial Denver field trials were followed up by further field trials by the Denver Public Works in September 2017 (and which are ongoing) to further evaluate the performance of EdenCrete® enriched concrete when exposed to de-icing salts and road chemicals (see Figure 3) (see Eden's ASX Announcement – ASX: EDE 18 September 2017).

Figure 2. EdenCrete® Trial Slabs in first trials.

Figure 3 – One of Two New Trial Sections of Concrete Pavement in second trials

The results in the published independent case study on the Denver field trials of EdenCrete® represent further very encouraging progress and are likely to be of considerable interest to other U.S. infrastructure agencies that are required to use de-icing salts and road chemicals on roads, walkways and other exposed concrete areas that are subject to snow and ice.

Commercial trials of an EdenCrete® ready mix concrete mix

During the year Eden completed the development with a Denver based ready mix company of a proprietary concrete mix that incorporates EdenCrete® in place of the welded wire mesh or macro fibres that have previously been used, targeting the building and replacement of concrete driveways. Driveways in Denver very frequently crack, even often in the first year, due to exposure to the many freeze-thaw events (when water freezes into ice and expands, then thaws and returns to water) that Denver experiences in a year. Denver has been reported in some years as experiencing more than 300 freeze-thaw events in a year. When concrete cures, shrinkage cracks are often formed which then fill with moisture and expand and contract with each freeze-thaw event, propagating the cracks and leading to a breaking up of the concrete.

Initially, four test driveways using the new EdenCrete® mix were laid and after being reviewed following two months use, the mix is now being used on a regular commercial basis in new and replacement driveways.

During the year, over 100 driveways using the new EdenCrete® mix had been laid using only EdenCrete® to combat shrinkage cracking, and this is expected to develop into a significant market, that will also have great relevance in many other States which also experience similar freeze-thaw events on a regular basis.

Denver Public Works specifies EdenCrete® by name for first time in Colorado

During the year, the City of Denver Public Works Department ("DPWD"), for the first time in Colorado, mandated by name, the use of EdenCrete® in specifications for concrete for a new project at the Evergreen Golf Club. Evergreen is located in the Rocky Mountains at an altitude of 7,220 feet (2,200 metres), 24 kilometres west of Denver, that experiences freezing conditions many times each year. This particular project was for the main slab and some surrounding apron work associated with the cart building. Specifically, EdenCrete was specified in order to increase durability, which includes improvements in freeze-thaw resistance, de-icer scaling, crack reduction and longer life.

This new project followed the evaluation, over two winters, of the performance of EdenCrete® in concrete roads in Denver in two separate field trials by DPWD (see Eden ASX announcements 20 February 2017 and 18 September 2017) in which the concrete was repeatedly subjected to freeze-thaw events and heavy dosages of de-icing salts and road chemicals that traditionally cause concrete to break down.

NEW YORK

EdenCrete®Pz Progress - Successful Truck Trials and Engineering Approval

Truck trials occurred during the year, with one significant sized New York based ready mix supplier, testing the benefits that EdenCrete®Pz delivers in new commercial pozzolanic concrete mixes for use in premier mid and high-rise applications in greater New York. These trials confirmed previous positive results, with economic and performance improvements versus the current standard commercial pozzolanic mixes.

Following these truck trials, successful laboratory trials of the high strength commercial air-entrained and non air-entrained concrete mix designs were undertaken by an independent laboratory that provides engineering-based certification of the designs.

The successful completion of these high-preforming concrete mixes now allows for use in commercial concrete production into the huge New York concrete market. Relevantly, the New York concrete market uses a significant amount of pozzolanic concrete in relation to which EdenCrete®Pz is of great relevance.

TEXAS

During the year, two new, more cost effective EdenCrete® concrete mix designs for use in prestressed concrete highway bridge beams were developed with the Texas based prestressed concrete producer that commenced using EdenCrete® in its concrete mixes designs in 2017, but which has not used it for the past year. Approval of these mix designs by the Texas Department of Transportation (TXDOT) is proposed to be completed in the near future, which is anticipated may result in a resumption of the regular sales of EdenCrete®.

NTPEP EVALUATION

Shortly after the end of the year, Eden was advised that NTPEP had completed evaluation of both EdenCrete® and EdenCrete® Pz. This followed the completion, during the year, of a 12 month trial by an independent laboratory appointed by NTPEP.

This opens the way for Eden to now apply to all of the U.S. State Departments of Transportation (DOTs) for both EdenCrete® and EdenCrete® Pz to be added to their Approved (or Qualified) Products Lists that will open the way for EdenCrete® and EdenCrete® Pz to be used in concrete on the State and Federal highways in each State

REVIEW OF OPERATIONS (Continued)

where approval has been obtained, and an application has now been made in South Carolina and further applications in other States will follow.

As previously announced (ASX: EDE 9 January 2018), EdenCrete® (but not EdenCrete® Pz) is already approved in 11 US States that did not require the NTPEP certification to be completed (Alaska, Arkansas, Colorado, Georgia, Mississippi, North Carolina, Oregon, Tennessee, Texas, Virginia and West Virginia (see Figure 4.). Relevantly, Virginia has recently approved a bridge trial and steps are underway to identify a suitable project.

Since the end of the year, South Carolina DOT has added both EdenCrete® and EdenCrete®Pz to its qualified products list, and Tennessee DOT, which had already approved EdenCrete®, has also added EdenCrete®Pz to its Approved Products list. The current position in relation to approvals of the EdenCrete® products is as set out on the map in Figure 4 below.

These 12 States now represent approximately:

- **26.5% of the total US population (over 82 million people);**
- **39,000 bridges that are structurally deficient or functionally obsolete, or**
- **27% of the total number of such bridges in the USA*.**

* DOT Fact Sheets Highlight Grim State of US Roads and Bridges – 9 July 2015

AUSTRALIA AND NEW ZEALAND EXCLUSIVE DISTRIBUTOR

In September 2018, Parchem Construction Supplies Pty Ltd ("Parchem"), a wholly owned subsidiary of Dulux Group Ltd, was appointed as the exclusive Australian and New Zealand distributor of the EdenCrete® range of products. Parchem has been servicing the Australian construction industry for over 50 years. It is a long-established marketer of a wide range of products that it either manufactures or distributes on behalf of other manufacturers. These products are sold for use in many facets of the concrete industry in both Australia and New Zealand, supplying contractors operating throughout many markets including infrastructure, buildings, power and mining.

Parchem has a wide geographical footprint with locations across Australia. It covers a broad spectrum of concrete applications. It is currently represented by an extensive Account Management team, focused on supporting customers on-site and providing solutions across its serviced industries. A National Specifications Team provides expertise to Architects, Engineers and Specifiers at multiple stages of projects. This experienced national sales and marketing network, supported by high level of in-house technical capacity, provides an ideal platform upon which Parchem can promote the EdenCrete® range over the next 3 years in Australia and New Zealand.



Figure 4. Current status of US DOT Approvals of EdenCrete® Products

The first Australian commercial trials commenced in April 2019 and subsequent to the end of the year Eden received, and dispatched, the first EdenCrete® order for Parchem. This follows internal trials by Parchem of the EdenCrete® products in Australian concrete.

Infrastructure Australia has responsibility to strategically audit Australia's nationally significant infrastructure, and develop 15 year rolling infrastructure plans that specify national and state level priorities. Following the release in February 2016 of its Australian Infrastructure Plan*, a large number of significant new infrastructure projects are now either underway or are being planned across Australia.

These projects represent key market targets for Eden, access to which may in part be assisted by the considerable progress that EdenCrete® has already made, and is continuing to make, in penetrating the huge infrastructure market in the United States of America through the delivery of more durable, longer lasting, stronger, tougher, less permeable concrete.

*http://infrastructureaustralia.gov.au/policy publications/publications/files/Australian_Infrastructure_Plan.pdf

KOREA

Trials undertaken in South Korea at Hanyang University to fully evaluate the potential of EdenCrete® products to enhance both the overall durability and other performance characteristics of Korean concrete (see Eden Quarterly Report to 31 December 2018 - ASX: EDE 10 January 2019) were completed during the year. A wide range of tests were undertaken in two different concrete mixes made with Portland cement and slag (designed for road pavement applications) and Portland cement and fly ash (designed for pre-cast concrete applications).

Highly encouraging results were achieved in 23 out of the 29 tests completed (including on some tests, the same test measured after as many as three different time periods). In the compressive strength tests, one mix, tested at three different time periods, resulted in three of the six, mostly small negative results that occurred. Possible further testing for chloride permeation and fire resistance did not occur as it was noted these tests would not provide conclusive results. The results achieved from the testing program include the following:

Durability and Strength Evaluation

	Concrete Pavement Concrete EdenCrete® HC +Pz added	Precast Concrete EdenCrete® Pz added
TEST	**% IMPROVEMENT**	**% IMPROVEMENT**
Ring-Test (shrinkage)	**Improved** concrete by delaying cracking by approx. **20%**	**No Cracks after 40 days** (end of trial). **Reference** cracked approx. **11 days**.
Drying shrinkage measurement	**Improved** concrete by reducing shrinkage strain by up to approx. **24.6%**	**Improved** concrete by reducing shrinkage strain by approx. **21.8%**
Plastic shrinkage cracking resistance	**Improved** concrete by reducing crack width by up to approx. **49.9%**	**Improved** concrete by reducing crack width by up to approx. **60.1%**
Amount of Water Permeation	**Improved** concrete by reducing quantity of permeated water by up to approx. **16%**	**Improved** concrete by reducing quantity of permeated water by up to approx. **7.5%**
Compressive Strength	**Improved** concrete by increasing compressive strength by up to approx. **9.7%**	**Reduced** compressive strength by up to approx. **8.9%**
Young's Modulus	**Improved** concrete by increasing Young's Modulus by up to approx. **11.13%**	**Improved** concrete by increasing Young's Modulus by up to approx. **10.6%**
Flexural Strength	**Improved** concrete by increasing flexural strength by up to approx. **15%**	**Improved** concrete by increasing flexural strength by up to approx. **15%**
Split Tensile strength	**Improved** concrete by increasing split tensile strength by up to approx. **6%**	**Improved** concrete by increasing split tensile strength by up to approx. **13.6%**

The Korean precast company with which Eden had been working has to date not decided to use EdenCrete® in its precast operations, due to limited early strength gains being achieved after 12 hours with the particular ferro-nickel pozzolanic concrete mix that it uses, and as a result Eden has commenced exploring other possible customers and distributors for EdenCrete® in South Korea. After preliminary talks with a number of parties, discussions have commenced with a highly technically qualified group that could potentially be a suitable EdenCrete® distributor in South Korea. These discussions are ongoing.

REVIEW OF OPERATIONS (Continued)

INDIA

EdenCrete® Indian marketing launched

Eden India, Eden's wholly owned Indian subsidiary that was established in 2007, held discussions during last quarter of the financial year with a number of India's leading companies involved in the construction, infrastructure and ready-mix concrete sectors and received strong preliminary interest in the potential use of EdenCrete®.

Eden India then arranged for representative samples of Indian cement and fly ash to be sent to Eden's Colorado laboratory for testing, and these were found to be encouragingly responsive to EdenCrete® products. In particular the fly ash mixes were highly responsive to EdenCrete®Pz.

Based on the US laboratory results, and supported by an EdenCrete® technical specialist, follow-up meetings with Indian groups involved in various sectors of the concrete industry have taken place since the end of the quarter in three major Indian cities. In all cases, EdenCrete® and the test results were extremely well received, with all groups now progressing to testing it in their own concrete mixes.

Additionally, the first Indian trial of EdenCrete® in concrete that included fly ash was undertaken in the laboratory of one company. After both three days and seven days, the tests have shown significant and highly encouraging improvement in early strength. These tests will continue as the concrete cures over the coming weeks.

Indian Fly Ash Supply

In April 2018, the Indian Ministry of Coal estimated that India had approximately 319 Billion tonnes of Geological Resources of coal, of which 280 Billion tonnes are classified as non-coking coal, including approximately 129 Billion tonnes of non-coking coal that are classified as "Proved/ Measured" [1].

Indian non-coking coal is mainly used in coal fired thermal power stations to generate electricity, fertiliser plants, cement furnaces and brick kilns.

Much of this non-coking coal contains high levels of silica, that when burnt produces a significant percentage (by weight) of fly ash. To minimise air pollution, the fly ash is largely captured in the smoke stacks of the furnaces, generating very large quantities of fly ash that are sold at very low prices or in many cases given away free of charge. In consequence, it is hoped that the addition of EdenCrete® products to concrete mixes may enable the percentage of the very low cost fly ash to be increased, thereby potentially strengthening the concrete as well as perhaps reducing its cost whilst also reducing its Greenhouse Gas footprint due to the fly ash itself being a waste by-product.

Indian Concrete Market

In India, a rapidly developing nation with a population of nearly 1.3 Billion people, the concrete market for all industrial, commercial and infrastructure applications, whilst already being large by global standards, is growing rapidly. To put this in context, in 2017, it is reported that the annual cement consumption in India reached 270 Million tonnes[2]. As commercial concrete mixes often contains up to or more than 20-30% (by weight) of cement, this is estimated to have resulted in the annual consumption of between approximately 800 Million tonnes – 1.3 Billion tonnes of concrete, or approximately 347 Million cubic metres - 565 Million cubic metres of concrete.

With the election commitment to allocate US$1.2 trillion towards infrastructure by recently re-elected Prime Minister Modi, India is a high priority target for EdenCrete® for infrastructure projects. Relevantly, during the past four years, the Indian Federal Minister for Transport and Roads (and who was re-appointed to the same portfolio after the recent election), is reported to have pushed the increase in the rate at which new Federal highways and roads were built (including a significant amount built using concrete), from two kilometres per day to thirty kilometres per day, and he has recently indicated he would like to again double that rate to sixty kilometres per day during the next four years.

The concrete mix that was recently trialled in India was one that is used in highway construction, and early indications are that the improvements in performance that the EdenCrete® products delivered may well enable not only better concrete to be produced, but that it may also be both cheaper and have a significantly lower Greenhouse Gas footprint. If these outcomes can be achieved, India is likely to become a major market for EdenCrete® products.

[1] https://coal.nic.in/content/coal-reserves

[2] https://www.statista.com/statistics/269322/cement-consumption-in-india-since-2004/

EUROPE

Successful initial trials with two European companies and discussions are continuing

Following discussions over the past 12 months and the execution of non-disclosure agreements, initial trials of EdenCrete® products have taken place with two European companies (each from a different country), including a large multinational construction company, that each expressed interest in using and perhaps also marketing EdenCrete® in various countries.

The results of the initial trials and the preliminary discussions with both have been very positive, with follow up trials and discussions now underway. Whilst these relationships are still in the early stages, the level of interest and positive initial results, and significant market potential that these companies provide are highly encouraging.

Interest has also been shown by a third European company, from a third country, and this will also be considered in due course.

JOINT RESEARCH PROJECTS

High strength CNT enriched concrete

The three-year research project with Deakin University ("Deakin"), partly funded by an Australian Research Council ("ARC") Linkage Grant, into ultra-high strength carbon nanotube enriched concrete, continued during the year with final trial work with EdenCrete® enriched concrete taking place.

OPTIBLEND® DUAL FUEL SYSTEM (EDEN 100%)

During the year Eden recorded the following Optiblend® sales, including sales in India to Bosch for 5 units worth A$161,000:

Optiblend® Invoiced Sales for 30 June 2019

	SALES (A$000's)
USA	405
INDIA	315
TOTAL	720

These sales for the year represent a year on year increase of 19% compared to the prior year, primarily driven by an increasing demand in India for the OptiBlend® dual fuel systems for back-up power supplies supplied by large diesel powered generator sets, with the increase in sales resulting from a combination of both attractive economics as well as from a national effort to reduce air pollution. Eden India has been self-funding for the past 20 months, based upon revenue generated from its OptiBlend® sales.

EDENPLAST™

The three-year research project with the University of Queensland ("UQ") for the development on a new method for producing carbon nanotube ("CNT") enriched thermoplastic composites, and which is partly funded by an Australian Research Council ("ARC") Linkage Grant, continued during the year, still focussing on bringing this project to commercialisation as soon as possible. The project has slowed as a result of a new researcher having recently taken over the task of completion of the project

Based on the success achieved to date, Eden has commenced preliminary investigations of possible commercial markets and partners for EdenPlast™ in both Australia and overseas.

A highlight of the work was that a concentrated master-batch of CNT- enriched plastic, containing a high concentration of CNT, was successfully prepared using a novel technique, bringing this project far closer to being ready for commercialisation. Further, the master batch then diluted with more plastic, bringing the mix to commercial concentration, and its performance characteristics were then tested, confirming that the process resulted in a potentially commercially viable end-product.

Following the lodgement of an earlier patent application (which was allowed by the US Patents Office in August 2019), a second patent application in relation to this novel technique was lodged by Eden during the year.

HYDROGEN

After a number of years when little external interest was shown in Eden's hydrogen production process and related technologies that it has successfully developed and commercialised, over the past year interest in these technologies has started to re-emerge, largely driven by its relatively low costs, low Greenhouse Gas footprint (no CO_2 is directly produced in the production of the hydrogen), and the significant value of the carbon that is produced in the process (being either carbon nanotubes or carbon nano-fibres).

Discussions with a multinational chemical company that expressed interest in Eden's hydrogen production process occurred over more than 12 months and culminated in a laboratory scale trial during the June 2019 quarter to measure the efficiency of Eden's hydrogen / carbon pyrolysis based production process to evaluate its potential for use as a low cost, low Greenhouse Gas emissions method to produce large quantities of relatively low cost hydrogen and carbon nanotubes or carbon nanofibres.

Whilst these trials produced encouraging results confirming the efficiency of the Eden process, at this stage as no external research funding was available to the third party to pursue further research into this project, no additional collaboration between the parties is currently planned. Eden may still consider exploring possible collaboration with other suitable third parties. However, with its staff being heavily committed on existing projects, this may not be a high priority objective for Eden, as at present this project is considered possibly more likely to lead only to longer term, rather than shorter term, market opportunities. However, Eden will periodically review this in case this situation should change.

Hydrogen Background

Whilst focusing heavily on hydrogen related activities between 2004 and 2012, Eden built, and still retains, a strong hydrogen technology base (comprising significant know how, techniques, designs and eight relevant patents), including Eden's patented pyrolysis process for production of hydrogen and carbon nanotubes/carbon nanofibres from natural gas (without producing carbon dioxide as a by-product), a patented blender for blending hydrogen and natural gas to create a highly efficient, low emission blend called Hythane® which Eden promoted for a number of years, particularly in India, and a patented hydrogen fuelled, internal combustion engine.

During this period, Eden built a hydrogen electrolyser and an operating Hythane® station for Indian Oil near the New Delhi airport (and which was still operating until recently), and developed Hythane® bus engines with Ashok Leyland, the largest Indian bus manufacturer.

Eden was also at that time working on joint ventures with various Indian natural gas suppliers to establish a number of Hythane® bus trials in various parts of India, but interest in hydrogen as a fuel started to wane after 2008, when US policy moved away from hydrogen as a vehicle fuel to electric vehicles. As a result none of these early developments in India progressed beyond the development and planning stages.

Over the past couple of years however, around the world there has been a growing increase in the level of interest in hydrogen as a fuel, in large part being driven by concern about climate change, which in turn has resulted in increased interest in Eden's hydrogen technologies.

Additionally, in India, extreme air pollution in Delhi and other cities is causing great concern, which has resulted in the Indian Supreme Court having mandated that the 10,000 strong, natural gas fuelled bus fleet in Delhi, be converted to run on a hydrogen based fuel, that in the short term is focusing on converting these buses to operate on Hythane®. This has again resulted in enquiries being received in relation to Eden's various hydrogen capabilities.

Similarly, in Australia, the Federal Government in 2018 allocated funds for research into the production of "clean hydrogen", opening a further area of possible interest for Eden for its now commercialised, pyrolysis process that produces, with a very low Greenhouse Gas footprint, both relatively low cost hydrogen and high value carbon nanotubes or carbon nanofibres.

DIRECTORS' REPORT

Your directors present their report on the Company and its controlled entities for the financial year ended 30 June 2019.

Directors

The names of directors in office at any time during or since the end of the year are:

Gregory H Solomon

Stephen D Dunmead

Douglas H Solomon

Lazaros Nikeas

Directors have been in office since the start of the financial year to the date of this report.

Company Secretary

The following person held the position of company secretary at the end of the financial year:

Mr Aaron P Gates has worked for Eden Innovations Ltd for the past 11 years. He is a Chartered Accountant and Chartered Secretary. He has completed a Bachelor of Commerce (Curtin University) with majors in accounting and business law and completed a Diploma of Corporate Governance. Prior to joining Eden he worked in public practice in audit and corporate finance roles.

Principal Activities

Eden Innovations Ltd produces and sells a high performance concrete admixture, EdenCrete® and retrofit dual fuel technology, OptiBlend®, developed for diesel generator sets.

There were no significant changes in the nature of the consolidated group's principal activities during the financial year.

Operating Results

The consolidated loss of the group after providing for income tax amounted to $9,216,320 (2018: $10,824,707).

Dividends Paid or Recommended

No dividends were paid or declared for payment during the year.

Review of Operations

A review of the operations of the Group during the year ended 30 June 2019 is set out in the Review of Operations on Page 4.

Financial Position

The net assets of the consolidated group have increased from $17,761,570 at 30 June 2018 to $21,039,734 at 30 June 2019. This increase is largely due to the capital raisings during the year. The group's working capital, being current assets less current liabilities, has decreased from $3,165,370 in 2018 to $2,853,033 in 2019.

Significant Changes in State of Affairs

There have been no significant changes in the state of affairs that occurred during the financial year.

After Balance Date Events

On 3 July 2019 4,634,624 fully paid ordinary shares were issued to Mr Stephen Dunmead and Mr Lazaros Nikeas pursuant to resolutions passed at the general meeting held on 2 July 2019.

On 3 September 2019 8,297,004 Class A Performance Rights (expiring on 31/8/2021 and vesting upon commercial revenue reaching US$6m over a rolling 12 month period), 8,297,004 Class B Performance Rights (expiring on 31/8/2022 and vesting upon commercial revenue reaching US$12m over a rolling 12 month period), 8,297,004 Class C Performance Rights (expiring on 31/8/2023 and vesting upon commercial revenue reaching US$24m over a rolling 12 month period) were issued in accordance with the Performance Rights Plan to employees and key consultants.

On 5 September 2019 58,160,000 fully paid ordinary shares were issued at $0.05 each pursuant to a Share Purchase Plan, raising $2,908,000.

No other matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Future Developments, Prospects and Business Strategies

The Group proposes to continue developing and marketing its technologies, including EdenCrete® and OptiBlend® as detailed in the Review of Operations.

Environmental Issues

The Group is subject to environmental regulation and complies fully with all requirements.

DIRECTORS' REPORT

Information on Directors

Gregory H Solomon	Executive Chairman	
Qualifications	**LLB**	
Experience	Appointed Executive Chairman in 2004. A qualified lawyer with more than 30 years' Australian and international experience in a wide range of areas including commercial negotiation and corporate law. Following 15 years' experience as a director on a number of ASX listed companies, for the past 15 years in his role as Executive Chairman he has been responsible for initiating and managing the entire business development of all companies in the Group since its incorporation.	
Interest in Shares and Options	45,369,342 Ordinary Shares	2,037,244 EDEOB Options
Directorships held in other listed entities	Tasman Resources Limited (ASX:TAS) Conico Limited (ASX:CNJ)	

Douglas H Solomon	Non-Executive Director	
Qualifications	**BJuris LLB (Hons)**	
Experience	Board member since May 2004. A Barrister and Solicitor with more than 30 years' experience in the areas of mining, corporate, commercial and property law. He is a partner in the legal firm, Solomon Brothers.	
Interest in Shares and Options	38,945,878 Ordinary Shares	1,756,633 EDEOB Options
Directorships held in other listed entities	Tasman Resources Limited (ASX:TAS) Conico Limited (ASX:CNJ)	

Lazaros Nikeas	Non-Executive Director
Qualifications	**B.A.**
Experience	Board member since May 2018. Mr Nikeas is an experienced investment and private equity professional with over 17 years of US finance experience. Mr Nikeas is currently a Principal investment manager for Weston Energy LLC, a portfolio company of New York private equity group, Yorktown Partners LLC. Prior to this, he was Lead Partner and Principal of Traxys Capital Partners, a private equity vehicle focused on mining, chemicals and industrial investments in partnership with The Carlyle Group. Before moving into private equity, he served as the Head of Corporate Finance Advisory for Materials, Mining and Chemicals for North America for BNP Paribas for five years. Other investment banking roles included Partner in Mergers & Acquisitions Advisory at Hill Street Capital for eight years and as a Corporate Finance Analyst at Morgan Stanley, where he began his career. Altogether, he has advised on over US$25 billion of mergers and acquisitions transactions.
Interest in Shares and Options	1,817,312 Ordinary Shares
Directorships held in other listed entities	-

Stephen D Dunmead	Non-Executive Director
Qualifications	**B.Sc., M.Sc., Ph.D.**
Experience	Board member since May 2018. Based in the US, Dr Dunmead is a global business executive with over 30 years of strong operational leadership experience in the US based global materials industry. He served as Chief Operating Officer at SWM International (NYSE: SWM) in Georgia where he was responsible for over 3,000 employees across 20 sites of the company's global operations in North and South America, Europe and Asia, accounting for US$0.8 billion of revenue and US$180 million in EBITDA. At SWM International he led the business into the high growth and high margin filtration and medical sectors. Prior to SWM International, Dr Dunmead spent over 15 years at OM Group (NYSE: OMG) in Ohio where he was a member of the Corporate Executive Team and had responsibility for six businesses with more than 6,500 employees across 32 sites in North America, Europe, Asia and Africa. Together, these businesses represented US$1.5 billion in revenue and US$255 million in EBITDA. Dr Dunmead holds 25 US Patents on Advanced Materials and Specialty Chemicals.
Interest in Shares and Options	2,817,312 Ordinary Shares
Directorships held in other listed entities	-

DIRECTORS' REPORT

REMUNERATION REPORT (AUDITED)

This report details the nature and amount of remuneration for each director of Eden Innovations Ltd, and for the executives receiving the highest remuneration.

Remuneration policy

The remuneration policy of Eden Innovations Ltd has been designed to align director and executive objectives with shareholder and business objectives by providing a fixed remuneration component and offering specific long-term incentives based on key performance areas affecting the consolidated Group's financial results. The board of Eden Innovations Ltd believes the remuneration policy to be appropriate and effective in its ability to attract and retain the best executives and directors to run and manage the consolidated Group, as well as create goal congruence between directors, executives and shareholders.

The board's policy for determining the nature and amount of remuneration for board members and senior executives of the economic entity is as follows:

- All executives receive a base salary (which is based on factors such as length of service and experience), superannuation (401k match), fringe benefits and options.

Executives are also entitled to participate in the employee share and option arrangements.

The executive directors receive superannuation, which is currently 9.5%, or 401k match and do not receive any other retirement benefits.

All remuneration paid to directors and executives is valued at the cost to the Company and expensed. Options are valued using the Black-Scholes methodology. The Group does not have a policy on directors hedging their shares.

The maximum aggregate amount of fees that can be paid to non-executive directors is subject to approval by shareholders at the Annual General Meeting. Fees for non-executive directors are not linked to the performance of the consolidated Group. However, to align directors' interests with shareholder interests, the directors are encouraged to hold shares in the Company and are able to participate in the employee share option plan.

Performance-based remuneration

No performance based remuneration was paid during the year.

Key Management Personnel Remuneration Policy

The Board's policy for determining the nature and amount of remuneration of management for the Group is as follows:

The remuneration structure for key management personnel is based on a number of factors, including length of service, particular experience of the individual concerned, and overall performance of the Company. The contracts for service between the Company and key management personnel are on a continuing basis, the terms of which are not expected to change in the immediate future. Upon retirement key management personnel are paid employee benefit entitlements accrued to date of retirement. Any ESOP options not exercised before or on the date of termination lapse.

Names and positions held of economic and parent entity key management personnel in office at any time during the financial year are:

Key Management Person - *Position*

Gregory H Solomon
Executive Chairman

Douglas H Solomon
Non-Executive Director

Lazaros Nikeas
Non-Executive Director

Stephen D Dunmead
Non-Executive Director

Roger W Marmaro
President Eden Innovations LLC

Aaron P Gates
Company Secretary / Chief Financial Officer

DIRECTORS' REPORT

Key Management Person	Short-term Benefits			Post-Employment Benefits	Other Long Term Benefits	Termination Benefits	Share- based Payments		Total
	Salary and Fees	Non-cash benefit	Other	Super-annuation	Other	Other	Equity	Options	
	$	$	$	$	$	$	$	$	$
2019									
Gregory Solomon	300,000	-	-	28,500	-	-	-	-	328,500
Douglas Solomon	54,000	-	-	5,130	-	-	-	-	59,130
Lazaros Nikeas	54,000	-	-	-	-	-	48,000	-	102,000
Stephen Dunmead(a)	267,256	-	-	-	-	-	88,000	-	355,256
Roger Marmaro(c)	586,906	32,830	-	25,188	-	-	-	116,410	761,334
Aaron Gates	(b)	-	-	-	-	-	-	5,873	5,873
	1,262,162	32,830	-	58,818	-	-	136,000	122,283	1,612,093
2018									
Gregory Solomon	300,000	-	-	28,500	-	-	-	-	328,500
Douglas Solomon	48,000	-	-	4,560	-	-	-	-	52,560
Lazaros Nikeas	9,000	-	-	-	-	-	-	19,200	28,200
Stephen Dunmead	26,028	-	-	-	-	-	-	19,200	45,228
Guy Le Page	39,000	-	-	3,705	-	-	-	-	42,705
Richard Beresford	39,000	-	-	3,705	-	-	-	-	42,705
Roger Marmaro	521,301	31,426	(d)120,300	18,642	-	-	-	302,632	994,301
Aaron Gates	(b)	-	-	-	-	-	-	12,622	12,622
	982,329	31,426	120,300	59,112	-	-	-	353,654	1,546,821

(a) Mr Stephen Dunmead provided short-term consulting services to the group during the period.

(b) This officer is provided by Princebrook Pty Ltd (a company in which Mr Gregory Solomon and Mr Douglas Solomon have an interest) under the Management services Agreement with the Company. During the year the Company paid $300,000 (2018: $300,000) to Princebrook Pty Ltd for management services.

(c) The appointment of Roger Marmaro may be terminated by giving not less than two months' written notice.

(d) Reimbursement of relocation costs (grossed up for tax) for R Marmaro relocating to Denver, Colorado at the request of the Company.

Other transactions with key management personnel

Management fees of $300,000 were paid/payable to Princebrook Pty Ltd, a company in which Mr GH Solomon and Mr DH Solomon have an interest.

Legal fees of $79,420, based on normal market rates, were paid to Solomon Brothers, a firm in which Mr GH Solomon and Mr DH Solomon are partners.

Under a resale price commitment agreement, between Eden Innovations LLC and R Marmaro, Eden Innovations LLC has agreed to reimburse R Marmaro for up to US$200,000 in lost home value if the employee was to sell his home at a loss on or before 31 January 2022, subject to certain exceptions.

DIRECTORS' REPORT

Number of Options Held by Key Management Personnel

	Balance 30.6.2018	Granted as Compensation	Options Exercised	Net Change* Other	Balance 30.6.2019	Total Vested 30.6.2019	Total Exercisable 30.6.2019	Total Unexercisable 30.6.2019
Gregory Solomon	-	-	-	2,037,244	2,037,244	2,037,244	2,037,244	-
Douglas Solomon	-	-	-	1,756,633	1,756,633	1,756,633	1,756,633	-
Lazaros Nikeas	2,400,000	-	-	-	2,400,000	1,600,000	1,600,000	800,000
Stephen Dunmead	2,400,000	-	-	-	2,400,000	1,600,000	1,600,000	800,000
Roger Marmaro	10,500,000	-	-	(500,000)	10,000,000	6,666,666	6,666,666	3,333,334
Aaron Gates	1,025,000	-	(75,000)	(491,250)	458,750	308,750	308,750	150,000
Total	16,325,000	-	(75,000)	2,802,627	19,052,627	13,969,293	13,969,293	5,083,334

* Net Change Other refers to options that have been purchased, sold, lapsed or issued during the year.

Number of Shares held by Key Management Personnel

	Balance 30.6.2018	Received as Compensation	Options Exercised	Net Change* Other	Balance 30.6.2019
Gregory Solomon	40,744,855	-	-	4,074,487	44,819,342
Douglas Solomon	35,132,614	-	-	3,513,264	38,645,878
Lazaros Nikeas	-	-	-	-	-
Stephen Dunmead	-	-	-	-	-
Roger Marmaro	2,478,648	-	-	-	2,478,648
Aaron Gates	100,000	-	75,000	17,500	192,500
Total	78,456,117	-	75,000	7,605,251	86,136,368

* Net Change Other refers to shares purchased or sold during the financial year.

<End of Remuneration Report>

Meetings of Directors

During the financial year, 6 meetings of directors were held. Attendances by each director during the year were as follows:

	Number eligible to attend	Number attended
Gregory H Solomon	6	6
Douglas H Solomon	6	6
Lazaros Nikeas	6	6
Stephen D Dunmead	6	6

Unissued shares under options

At the date of this report, the unissued ordinary shares of Eden Innovations Ltd under option are as follows:

Issue Date	Date of Expiry	Exercise Price	Number under Option
Various	28 February 2020	$0.27	24,729,422
28 August 2017	30 November 2020	$0.25	330,000
8 March 2019	8 March 2021	$0.08	69,699,634
20 June 2019	1 June 2021	$0.07	6,000,000
20 June 2019	1 June 2021	$0.08	6,000,000
			106,759,056

DIRECTORS' REPORT

The Options expiring on 28 February 2020 and 30 November 2020 are all held, pursuant to the Company's Employee Share Option Plan, by overseas employees or directors of subsidiaries of the Company or key consultants. No person entitled to exercise the option has any right by virtue of the option to participate in any share issue of any other body corporate.

At the date of this report unissued shares of the Group under performance rights are 24,891,012.

Indemnifying Officers or Auditor

The Company has arranged for an insurance policy to insure the directors against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of director of the Company, other than conduct involving a wilful breach of duty in relation to the Company. The total premium payable was approximately $102,336.

Proceedings on Behalf of Company

No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

Non-audit Services

The Board of Directors is satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The directors are satisfied that the services disclosed below did not compromise the external auditor's independence for the following reasons:

- the nature of the services provided do not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants set by the Accounting Professional and Ethical Standards Board.

No fees for non-audit services were paid / payable to the external auditors during the year ended 30 June 2019.

Auditor's Independence Declaration

The lead auditor's independence declaration for the year ended 30 June 2019 has been received and can be found on page 19.

Rounding of amounts

Eden Innovations Ltd is a type of Company referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191 and therefore the amounts contained in this report and in the financial report have been rounded to the nearest $1.

Signed in accordance with a resolution of the Board of Directors.

Gregory H Solomon

Executive Chairman

Dated this 20th day of September 2019

Nexia Australia

Lead auditor's independence declaration under section 307C of the *Corporations Act 2001*

To the directors of Eden Innovations Ltd

I declare that, to the best of my knowledge and belief, in relation to the audit for the financial year ended 30 June 2019 there have been:

(i) no contraventions of the auditor's independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and

(ii) no contraventions of any applicable code of professional conduct in relation to the audit.

NPAS

Nexia Perth Audit Services Pty Ltd

M. Janse Van Nieuwenhuizen | Director

Perth
20 September 2019

Nexia Perth
Audit Services Pty Ltd
ACN 145 447 105
Level 3, 88 William Street
Perth WA 6000
GPO Box 2570, Perth WA 6001
p +61 8 9463 2463
f +61 8 9463 2499
e audit@nexiaperth.com.au
w nexia.com.au

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR YEAR ENDED 30 JUNE 2019

	Note	Consolidated Group	
		2019	**2018**
		$	**$**
Revenue	2	2,334,901	1,317,960
Other income		28,046	5,252
Changes in inventories		82,586	(4,128)
Raw materials and consumables used		(489,447)	(204,404)
Depreciation and amortisation expense		(1,089,362)	(1,023,344)
Employee benefits expense	3a	(5,526,330)	(7,355,821)
Finance costs		(34,167)	(24,572)
Other financial items	4	(8,893)	(94,748)
Other expenses		(4,587,341)	(3,623,225)
Loss before income tax		(9,290,007)	(11,007,030)
Income tax (expense)/benefit	7	73,687	182,323
Loss for the year		(9,216,320)	(10,824,707)
Other Comprehensive Income / (Loss)			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation reserve		622,754	418,570
Income tax relating to comprehensive income		-	-
Total Other Comprehensive Income / (Loss), net of tax		622,754	418,570
Total Comprehensive Income / (Loss) attributable to members of the parent		(8,593,566)	(10,406,137)
Basic/Diluted loss per share (cents per share)	6	(0.5969)	(0.8267)

The accompanying notes form part of these financial statements.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2019

	Note	Consolidated Group	
		2019	2018
		$	$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	9	3,217,555	3,489,730
Trade and other receivables		315,267	309,656
Inventories	10	735,290	617,320
Other current assets		58,307	117,630
TOTAL CURRENT ASSETS		4,326,419	4,534,336
NON-CURRENT ASSETS			
Property, plant and equipment	11	12,463,621	10,690,384
Intangible assets	12	6,524,192	4,907,542
TOTAL NON-CURRENT ASSETS		18,987,813	15,597,926
TOTAL ASSETS		23,314,232	20,132,262
CURRENT LIABILITIES			
Trade and other payables	13	1,069,010	1,049,639
Interest bearing liabilities	14	247,422	230,058
Provisions	15	156,954	89,269
TOTAL CURRENT LIABILITIES		1,473,386	1,368,966
NON-CURRENT LIABILITIES			
Interest bearing liabilities	14	772,355	984,296
Other liabilities		28,757	17,430
TOTAL NON-CURRENT LIABILITIES		801,112	1,001,726
TOTAL LIABILITIES		2,274,498	2,370,692
NET ASSETS		21,039,734	17,761,570
EQUITY			
Issued capital	16	102,636,700	91,230,956
Reserves	20	8,953,733	7,864,993
Accumulated losses		(90,550,699)	(81,334,379)
TOTAL EQUITY		21,039,734	17,761,570

The accompanying notes form part of these financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR YEAR ENDED 30 JUNE 2019

	Consolidated Group				
	Fully Paid Ordinary Shares	Option Reserve	Foreign Currency Translation Reserve	Accumulated Losses	Total
	$	$	$	$	$
Balance at 30 June 2017	83,385,716	6,911,632	(222,354)	(70,509,672)	19,565,322
Shares issued during the year, net of issue costs	7,845,240	-	-	-	7,845,240
Options issued during the year	-	757,145	-	-	757,145
Loss for year	-	-	-	(10,824,707)	(10,824,707)
Other comprehensive income	-	-	418,570	-	418,570
Total comprehensive income/(loss)	-	-	418,570	(10,824,707)	(10,406,137)
Balance at 30 June 2018	91,230,956	7,668,777	196,216	(81,334,379)	17,761,570
Shares issued during the year, net of issue costs	11,405,744	-	-	-	11,405,744
Options issued during the year	-	465,986	-	-	465,986
Loss for year	-	-	-	(9,216,320)	(9,216,320)
Other comprehensive income	-	-	622,754	-	622,754
Total comprehensive income/(loss)	-	-	622,754	(9,216,320)	(8,593,566)
Balance at 30 June 2019	102,636,700	8,134,763	818,970	(90,550,699)	21,039,734

The accompanying notes form part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS FOR YEAR ENDED 30 JUNE 2019

	Note	Consolidated Group	
		2019	**2018**
		$	**$**
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		2,400,657	1,013,433
Payments to suppliers and employees		(9,623,820)	(10,380,806)
Income taxes (paid)/received		73,687	182,323
Interest paid		(27,677)	(24,572)
Interest received		3,167	5,252
Net cash used in operating activities	18	(7,173,986)	(9,204,370)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	11	(1,980,308)	(1,350,253)
Payment for research and development	12	(2,068,407)	(1,514,619)
Net cash used in investing activities		(4,048,715)	(2,864,872)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from issue of shares, net of issue costs		11,298,297	7,845,240
Repayment of borrowings		(355,086)	(221,740)
Net cash provided by financing activities		10,943,211	7,623,500
Net increase/(decrease) in cash held		(279,490)	(4,445,742)
Net increase/(decrease) due to foreign exchange movements		7,315	(49,254)
Cash at beginning of financial year		3,489,730	7,984,726
Cash at end of financial year	9	3,217,555	3,489,730

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board and the *Corporations Act 2001*. The financial report complies with all International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board in their entirety.

The financial report covers the consolidated Group of Eden Innovations Ltd and its controlled entities as at and for the year ended 30 June 2019. Eden Innovations Ltd is a listed public company, incorporated and domiciled in Australia. The Group is a for-profit entity and primarily is involved in clean technology solutions.

The financial report was authorised for issue on 20 September 2019 by the Board of Directors.

The following is a summary of the material accounting policies adopted by the consolidated Group in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

Basis of Preparation

The accounting policies set out below have been consistently applied to all years presented.

Reporting Basis and Conventions

The financial report has been prepared on an accruals basis and is based on historical costs modified by the revaluation of selected non-current assets, financial assets and financial liabilities for which the fair value basis of accounting has been applied. These consolidated financial statements are presented in Australian dollars, which is the Parent's functional currency. The subsidiaries' functional currencies are USD and INR.

Going Concern

These financial statements have been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and extinguishment of liabilities in the ordinary course of business.

The Group has reported a net loss for the year of $9,216,320 (2018: $10,824,707) and a cash outflow from operating activities of $7,173,986 (2018: $9,204,370). The directors carefully manage expenditure and, subject to being able to raise further finance, are of the view, based on cash flow forecasts, that the Group will be able to continue its operations as a going concern.

The continuing applicability of the going concern basis of accounting is dependent upon the Group's ability to source additional finance. The directors are confident that the Group will be successful in securing additional funds, should the need arise.

Based on these facts, the directors consider the going concern basis of preparation to be appropriate for this financial report. Should the Company be unsuccessful in securing additional finance, there is a material uncertainty which may cast significant doubt whether the entity will be able to continue as a going concern and therefore, whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial report.

The financial statements do not include any adjustments relative to the recoverability and classification of recorded asset amounts or, to the amounts and classification of liabilities that might be necessary should the entity not continue as a going concern.

Accounting Policies

a. Principles of Consolidation

A controlled entity is any entity Eden Innovations Ltd is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. A list of controlled entities is contained in Note 21 to the financial statements. All controlled entities have a June year-end.

All inter-company balances and transactions between entities in the consolidated group, including any unrealised profits or losses, have been eliminated on consolidation. Accounting policies of subsidiaries have been changed where necessary to ensure consistencies with those policies applied by the parent entity.

b. Income Tax

The charge for current income tax expense is based on the profit for the year adjusted for any non-assessable or disallowed items. It is calculated using the tax rates that have been enacted or are substantially enacted by the balance sheet date.

Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding a business combination, where there is no effect on accounting or taxable profit or loss. Deferred income tax assets are recognised to the extent that it is probable that future tax profits will be available against which deductible temporary differences can be utilised.

Eden Innovations Ltd, Eden Innovations Holdings Pty Ltd and Eden Energy Holdings Pty Ltd, its wholly-owned Australian subsidiaries, have formed an income tax

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

consolidated group under the tax consolidation regime. The Group notified the Australian Tax Office that it had formed an income tax consolidated group to apply from 1 July 2005. The tax consolidated group has entered a tax sharing agreement whereby each company in the group contributes to the income tax payable in proportion to their contribution to the net profit before tax of the tax consolidated group. The R&D tax rebate is recognised as income tax benefit upon receipt.

c. Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of manufactured products includes direct materials, direct labour and an appropriate portion of variable and fixed overheads. Costs are assigned on the basis of first-in, first-out.

d. Segment reporting

Segment results that are reported to the Group's board of directors (the chief operating decision maker) include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

e. Employee Benefits

Provision is made for the company's liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.

f. Revenue

Revenue is recognised when or as the Group transfers control of products or provides services to a customer at the amount to which the Group expects to be entitled as the performance obligation is met. If the consideration includes a variable component, the expected consideration is adjusted for the estimated impact of the variable component at the point of recognition and re-estimated at every reporting period. Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

g. Property, Plant and Equipment

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation and impairment losses.

Plant and equipment

Plant and equipment are initially recognised at acquisition cost or manufacturing cost, including any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by the Group's management.

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount of these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

The depreciation rates used for each class of depreciable assets are:

Class of Fixed Asset	Depreciation Rate
Plant and equipment	15 – 50% straight line
Buildings	4% straight line

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the income statement. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

h. Financial Instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions of the financial instrument. Financial assets are initially measured at fair value adjusted for transaction costs.

Classification and subsequent measurement

For the purpose of subsequent measurement, financial assets are classified into the following categories:

- amortised cost
- fair value through profit or loss (FVTPL)
- equity instruments at fair value through other comprehensive income (FVOCI)
- debt instruments at fair value through other comprehensive income (FVOCI).

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items. The classification is determined by both the entity's business model for managing the financial asset and the contractual cash flow characteristics of the financial asset.

Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVTPL):

- they are held within a business model whose objective is to hold the financial assets to collect its contractual cash flows

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

- the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding.

After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The entity's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments.

Trade and other receivables

The entity makes use of a simplified approach in accounting for trade and other receivables and records the loss allowance as lifetime expected credit losses. These are the expected shortfalls in contractual cash flows, considering the potential for default at any point during the life of the financial instrument. In calculating, the entity uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses.

Classification and measurement of financial liabilities

The entity's financial liabilities include trade and other payables. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs.

Subsequently, financial liabilities are measured at amortised cost using the effective interest method. All interest-related charges and, if applicable, changes in an instrument's fair value that are reported in profit or loss are included within finance costs or finance income.

Derecognition

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and substantially all the risks and rewards are transferred.

A financial liability is derecognised when it is extinguished, discharged, cancelled or expires.

Impairment

The Group recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss.

i. Impairment of Assets

At each reporting date, the group reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the income statement.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

Where it is not possible to estimate the recoverable amount of an individual asset, the group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

j. Intangibles

Research and development

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.

Development costs have a finite life and are amortised on a systematic basis matched to the future economic benefits over the useful life of the project.

Intellectual Property

Intellectual property, which includes trademarks and engineering knowledge, is included in the financial statements at cost, being their fair value on acquisition.

Intellectual property and trademarks are only amortised or written down where the useful lives are limited or impaired by specific circumstances, in such cases amortisation is charged on a straight line basis over their useful lives and write downs are charged fully when incurred. The directors have assessed the useful life of the intellectual property and have determined that it has a finite useful life of 10 to 20 years. The intellectual property is amortised on a systematic basis matched to the expected future economic benefits over the useful life of the project.

k. Foreign Currency Transactions and Balances

Functional and presentation currency

The functional currency of each of the group's entities is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

Transaction and balances

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

Exchange differences arising on the translation of monetary items are recognised in the income statement.

Group companies

The financial results and position of foreign operations whose functional currency is different from the group's presentation currency are translated as follows:

- assets and liabilities are translated at year-end exchange rates prevailing at that reporting date;
- income and expenses are translated at average exchange rates for the financial year; and
- retained earnings are translated at the exchange rates prevailing at the date of the transaction.

Exchange differences arising on translation of foreign operations are transferred directly to the group's foreign currency translation reserve in the balance sheet. These differences are recognised in the income statement in the period in which the operation is disposed. Intercompany loans are treated as investments for foreign currency translation purposes.

l. Equity-settled compensation

The group operates an employee share option plan. The total amount to be expensed over the vesting period is determined by reference to the fair value of the shares of the options granted.

m. Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

n. Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares are recognised as a deduction from equity.

o. New accounting standards and interpretations

New and amended standards adopted by the Group

The Group has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective for the current year, including AASB 9 and AASB 15. The new and revised Standards and amendments thereof and Interpretations do not have any material impact on the disclosures or on the amounts recognised in the Group's consolidated financial statements.

AASB 9 Financial Instruments – There were no changes required to the consolidated financial report to recognise the revised requirements of AASB 9.

AASB 15 Revenue – The Group recognises revenue when the goods are shipped to the customer or for services when the services have been completed and the performance obligation has been met, this is in line with AASB 15 and has not resulted in any changes.

Impacts of standards issued but not yet adopted by the Group

AASB 16 Leases – The standard will primarily affect the group's operating leases. As at the reporting date the group had only low value leases and the impact on the financial statements is not expected to be material.

Critical Accounting Estimates and Judgments

The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Group.

Key Estimates — Impairment

The Group assesses impairment of finite intangible assets and property, plant & equipment at each reporting date by evaluating conditions specific to the Group that may lead to impairment of assets. At the date of this report the Group has sufficient reason to believe that the Group's intangible assets and property, plant & equipment are not impaired.

There is a significant risk of actual outcomes being different from those forecasted due to changes in economic or market conditions and events.

Key Estimates — Share-based payment transactions

The consolidated entity measures the cost of equity settled transactions with suppliers and employees by reference to the fair value of the equity instruments as at the date at which they are granted. The fair value is determined using a Black-Scholes model. Refer to Note 3b for the inputs to the Black-Scholes model.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

NOTE 2: REVENUE	**2019 $**	**2018 $**
Operating activities		
- EdenCrete® sales	1,614,546	711,683
- OptiBlend® sales and services	720,355	606,277
Total revenue	2,334,901	1,317,960

NOTE 3: EMPLOYEE BENEFITS

	2019 $	**2018 $**
a. Employee benefits expense		
Expenses recognised for employee benefits are analysed below:		
Short-term employee benefits	(4,825,750)	(6,277,094)
Post-employment benefits	(246,650)	(274,575)
Termination benefits	-	(47,007)
Share based payments	(453,930)	(757,145)
Total	(5,526,330)	(7,355,821)

b. Share-based Employee Remuneration

All options granted to personnel are over ordinary shares in Eden Innovations Ltd, which confer a right of one ordinary share for every option held. When issued, the shares carry full dividend and voting rights.

	2019		**2018**	
	Number of Options	**Weighted Average Exercise Price $**	**Number of Options**	**Weighted Average Exercise Price $**
Outstanding at the beginning of the year	36,382,462	0.234	33,056,843	0.238
Granted	-	-	5,300,000	0.206
Exercised	-	-	-	-
Lapsed	(6,523,040)	0.117	(1,974,381)	0.222
Outstanding at year-end	29,859,422	0.226	36,382,462	0.234
Exercisable at year-end	18,383,173	0.226	15,660,821	0.201

The options outstanding at 30 June 2019 had a weighted average exercise price of $0.226 and a weighted average remaining contractual life of 0.94 years.

Historical volatility has been the basis for determining expected share price volatility as it is assumed that this is indicative of future tender, which may not eventuate. Volatility of 52-82% and a risk free rate of 1.5-2.24% were used in the Black-Scholes model. The life of the options is based on the historical exercise patterns, which may not eventuate in the future.

No options were exercised during the year ended 30 June 2019. Included under employee benefits expense in the income statement is $453,930 (2018: $757,145) and relates, in full, to equity settled share-based payment transactions.

NOTE 4: OTHER FINANCIAL ITEMS

	2019 $	**2018 $**
Foreign exchange gain / (loss)	(8,893)	(77,311)
Impairment expense	-	(17,437)
Total	(8,893)	(94,478)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2018

NOTE 5: AUDITORS' REMUNERATION

	2019 $	2018 $
Remuneration of the auditor of the parent entity for:		
— auditing or reviewing the financial report	50,428	48,100
— other services	-	-
Remuneration of other auditors of subsidiaries for:		
— auditing or reviewing the financial report	56,116	62,784
— other services	-	7,353

NOTE 6: EARNINGS PER SHARE

		2019 $	2018 $
a.	Reconciliation of earnings to profit or loss		
	Profit/(loss)	(9,216,320)	(10,824,707)
	Earnings used to calculate basic EPS	(9,216,320)	(10,824,707)
b.	Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS	1,544,110,867	1,309,434,644

The options on issue are not potentially dilutive shares.

NOTE 7: INCOME TAX BENEFIT

			2019 $	2018 $
a.	The prima facie tax on loss from ordinary activities before income tax is reconciled to the income tax as follows:			
	Prima facie tax payable on loss from ordinary activities before income tax at 27.5% (2018: 26.5%)		(2,534,488)	(2,916,863)
	Add tax effect of:			
	—	Non-deductible expenses	7,169	135,741
	—	Current year tax losses not recognised	5,932,632	2,358,362
	Less tax effect of:			
	—	Effect of change in tax rate	-	(1,697,411)
	—	Current year temporary differences not recognised	(3,479,000)	2,269,424
	Income tax expense/(benefit)		(73,687)	(182,323)
b.	Components of deferred tax			
	—	Unrecognised deferred tax asset – losses	28,837,949	22,977,953
	—	Property, Plant & Equipment	(1,310,200)	(988,148)
	—	Capital raising costs	307,926	360,378
	—	Stock compensation	409,985	341,306
	—	Provisions and accruals	111,640	25,954
	—	Intangibles	(2,099,838)	(1,585,165)
	Total unrecognised deferred tax asset		26,257,462	21,132,278

Deferred tax assets have not been brought to account as it is not probable within the immediate future that tax profits will be available against which deductible temporary differences and tax losses can be utilised. The benefit of the tax losses will only be obtained if the Group complies with conditions imposed by the relevant tax legislation.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 8: RELATED PARTY TRANSACTIONS

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated. Full details of key management personnel remuneration can be found in the remuneration report on page 15.

	2019 $	2018 $
Key Management Personnel		
Management fees paid/payable to Princebrook Pty Ltd, a company in which Mr GH Solomon and Mr DH Solomon have an interest.	300,000	300,000
Legal fees paid to Solomon Brothers, a firm in which Mr GH Solomon and Mr DH Solomon are partners. At year end, 3,830 of fees were payable (2019: $nil)	79,420	31,656

Under a resale price commitment agreement between Eden Innovations LLC and R Marmaro, Eden Innovations LLC has agreed to reimburse R Marmaro for up to US$200,000 in lost home value if the employee was to sell his home at a loss on or before 31 January 2022, subject to certain exceptions.

NOTE 9: CASH AND CASH EQUIVALENTS

	2019 $	2018 $
Cash at bank and in hand	3,217,555	3,489,730
	3,217,555	3,489,730
Reconciliation of cash		
Cash at the end of the financial year as shown in the statement of cash flows is reconciled to the consolidated statement of financial position as follows:		
Cash and cash equivalents	3,217,555	3,489,730
	3,217,555	3,489,730

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 10: INVENTORIES

	2019 $	2018 $
At cost	735,290	617,320
	735,290	617,320

NOTE 11: PROPERTY, PLANT AND EQUIPMENT

	Land and buildings	Plant and equipment	Total
Cost			
Balance 1 July 2018	4,677,346	7,112,611	11,789,957
Additions	1,706,089	445,637	2,151,726
Transfers	105,114	(105,114)	-
Disposals	-	(92,615)	(92,615)
Net exchange differences	276,634	264,558	541,192
Balance 30 June 2019	6,765,183	7,625,077	14,390,260
Depreciation and impairment			
Balance 1 July 2018	(249,149)	(850,424)	(1,099,573)
Depreciation	(203,859)	(552,407)	(756,266)
Net exchange differences	(15,216)	(55,584)	(70,800)
Balance 30 June 2019	(468,224)	(1,458,415)	(1,926,639)
Carrying amount at 30 June 2019	6,296,959	6,166,662	12,463,621
Cost			
Balance 1 July 2017	3,881,417	7,313,797	11,195,214
Additions	35,315	597,655	632,970
Transfers	587,470	(587,470)	-
Disposals	-	(462,561)	(462,561)
Net exchange differences	173,144	251,190	424,334
Balance 30 June 2018	4,677,346	7,112,611	11,789,957
Depreciation and impairment			
Balance 1 July 2017	(67,452)	(664,482)	(731,934)
Depreciation	(168,638)	(509,738)	(678,376)
Disposals	-	363,483	363,483
Net exchange differences	(13,059)	(39,687)	(52,746)
Balance 30 June 2018	(249,149)	(850,424)	(1,099,573)
Carrying amount at 30 June 2018	4,428,197	6,262,187	10,690,384

Capitalised costs amounting to $1,983,077 (2018: $1,350,253) have been included in cash flows from investing activities in the statement of cash flows for the Consolidated Group.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 12: INTANGIBLE ASSETS	**2019 $**	**2018 $**
Intellectual property	17,131,915	15,153,388
Accumulated amortisation	(1,188,807)	(826,930)
Accumulated impairment expenses	(9,418,916)	(9,418,916)
Net carrying value	6,524,192	4,907,542
Balance at the beginning of the year	4,907,542	3,711,401
Additions	2,068,407	1,558,546
Amortisation expense	(451,757)	(344,968)
Impairment	-	(17,437)
Carrying amount at the end of the year	6,524,192	4,907,542

Intellectual property relates to pyrolysis technology, EdenCrete®, EdenPlastTM and OptiBlend®. Capitalised costs amounting to $2,065,638 (2018: $1,514,619) have been included in cash flows from investing activities in the statement of cash flows.

NOTE 13: TRADE AND OTHER PAYABLES

Trade payables and other payables	1,069,010	1,049,639
	1,069,010	1,049,639

NOTE 14: INTEREST BEARING LIABILITIES

Relates to the loan for the purchase of the Dumont Way property. It is secured over the property, repayable in six equal annual installments, carries an interest rate of 2% and is denominated in US dollars.

Current portion	247,422	230,058
Non-current portion	772,355	984,296
	1,019,777	1,214,354

NOTE 15: PROVISIONS

Provisions for staff entitlements and warranties	156,954	89,269
	156,954	89,269

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 16: ISSUED CAPITAL		**2019 No.**	**2018 No.**	**2019 $**	**2018 $**
a.	**Ordinary shares**				
	At the beginning of reporting period	1,382,990,110	1,262,172,800	91,230,956	83,385,716
	Shares issued during the year	277,811,632	120,817,310	11,405,744	7,845,240
	At reporting date	1,660,801,742	1,382,990,110	102,636,700	91,230,956

i. The ordinary shares on issue have no par value and there is no limited amount of authorised share capital.

ii. Ordinary shares participate in dividends and in the proceeds on winding up of the parent entity in proportion to the number of shares held. At the shareholders meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

		2019 No.	**2018 No.**
b.	**Options**		
	At the beginning of reporting period	215,279,588	275,268,282
	Options issued	81,700,834	5,300,000
	Options exercised	(138,410,209)	(63,314,313)
	Options lapsed	(47,011,157)	(1,974,381)
	At reporting date	111,559,056	215,279,588

For information relating to the Eden Innovations Ltd employee option plan, refer to Note 3b Share-based Payments.

c. Capital Management

Management controls the working capital of the Group in order to maximise the return to shareholders and ensure that the Group can fund its operations and continue as a going concern. Management effectively manages the Group's capital by assessing the Group's financial risks and adjusting its capital structure in response to changes in these risks and in the market. These responses include the management of expenditure and share issues. There have been no changes in the strategy adopted by management to control the capital of the Group since the prior year.

NOTE 17: CONTINGENT LIABILITIES AND CONTINGENT ASSETS

Under a resale price commitment agreement between Eden Innovations LLC and an employee, Eden Innovations LLC has agreed to reimburse the employee for up to US$200,000 in lost home value if the employee was to sell his home at a loss on or before 31 January 2022, subject to certain exceptions.

The Directors are not aware of any other contingent assets or contingent liabilities at 30 June 2019.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 18: CASH FLOW INFORMATION

Reconciliation of Cash Flow from Operations with Loss after Income Tax	**2019 $**	**2018 $**
Loss after income tax	(9,216,320)	(10,824,707)
Non-cash flows in loss		
Depreciation and amortisation	1,089,362	1,023,344
Share-based payments expense	601,985	757,145
Other financial items	8,893	94,748
Assets written off	92,615	-
Net exchange differences	(26,561)	19,941
Changes in assets and liabilities, net of the effects of purchase and disposal of subsidiaries		
(Increase)/decrease in trade and other receivables	(5,611)	(206,235)
(Increase)/decrease in inventories	(117,970)	(4,128)
(Increase)/decrease in other current assets	59,323	(12,786)
Increase/(decrease) in trade payables and accruals*	404,407	(71,038)
Increase/(decrease) in provisions	(75,436)	1,916
Increase/(decrease) in other liabilities	11,327	17,430
Cash flow from operations	(7,173,986)	(9,204,370)

* - Net of non-operating movements

NOTE 19: CAPITAL AND LEASING COMMITMENTS

a. Capital Expenditure Commitments

— not later than 12 months	-	-
— greater than 12 months	-	-
	-	-

b. Other Commitments

None

NOTE 20: RESERVES

a. Option Reserve

The option reserve records items recognised as expenses on valuation of share options.

b. Foreign Currency Translation Reserve

The foreign currency translation reserve records exchange differences arising on the translation of foreign subsidiaries.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 21: CONTROLLED ENTITIES

a. Controlled Entities

Controlled Entities	Country of Incorporation	Percentage Owned (%)* 2019	2018
Eden Innovations Holdings Pty Ltd (formerly Adamo Energy Ltd)	Australia	100	100
Eden Innovations (India) Pvt Ltd	India	100	100
Eden Energy Holdings Pty Ltd	Australia	100	100
Eden Innovations LLC	USA	100	100
EdenCrete Industries Inc.	USA	100	100

** Percentage of voting power is in proportion to ownership*

b. Acquisition of Controlled Entities

No entities were acquired during the year.

c. Disposal of Controlled Entities

No entities were disposed of during the year.

NOTE 22: PARENT COMPANY INFORMATION

	2019 $	2018 $
a. Parent Entity		
Assets		
Current assets	2,610,983	3,013,785
Non-current assets (includes intercompany receivables of $39,225,942)*	62,991,461	53,593,284
Total Assets	65,602,444	56,607,069
Liabilities		
Current liabilities	234,568	229,091
Total liabilities	234,568	229,091
Equity		
Issued Capital	102,636,701	91,230,956
Retained Earnings	(45,399,552)	(42,517,015)
Reserves		
Option reserve	8,130,023	7,664,038
Total reserves	8,130,023	7,664,038
Financial performance		
Profit / (Loss) for the year	(2,882,537)	(2,217,294)
Other comprehensive income, net of tax	-	-
Total comprehensive income / (Loss)	(2,882,537)	(2,217,294)

* - The intercompany receivables have been assessed for impairment and management do not consider a provision for impairment against these receivables is required. It is anticipated that these receivables will be recovered through the successful commercialisation of EdenCrete® and OptiBlend® by the subsidiary companies.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 23: EVENTS AFTER THE BALANCE SHEET DATE

On 3 July 2019 4,634,624 fully paid ordinary shares were issued to Mr Stephen Dunmead and Mr Lazaros Nikeas pursuant to resolutions passed at the general meeting held on 2 July 2019.

On 3 September 2019 8,297,004 Class A Performance Rights (expiring on 31/8/2021 and vesting upon commercial revenue reaching US$6m over a rolling 12 month period), 8,297,004 Class B Performance Rights (expiring on 31/8/2022 and vesting upon commercial revenue reaching US$12m over a rolling 12 month period), 8,297,004 Class C Performance Rights (expiring on 31/8/2023 and vesting upon commercial revenue reaching US$24m over a rolling 12 month period) were issued in accordance with the Performance Rights Plan to employees and key consultants.

On 5 September 2019 58,160,000 fully paid ordinary shares were issued at $0.05 each pursuant to a Share Purchase Plan, raising $2,908,000.

There were no other material events occurring after the reporting date.

NOTE 24: SEGMENT REPORTING

The Group has identified its operating segments based on internal reports that are reviewed and used by the Board of Directors (chief operating decision maker) in assessing performance and determining allocation of resources. Activities of the Group are managed on Group structure basis and operating segments are therefore determined on the same basis. In this regard the following list of reportable segments has been identified.

- Eden Innovations LLC – EdenCrete® sales and development and Optiblend® sales, service and manufacturing.
- Eden Innovations (India) Pvt Ltd – Optiblend® sales, service and manufacturing in India.

	Eden Innovations LLC	Eden Innovations India Pvt Ltd	Eliminations	Consolidated Entity
	$	$	$	$
2019				
External sales	2,021,064	313,837	-	2,334,901
Internal sales	1,920,087	-	(1,920,087)	-
Total segment revenue	3,941,151	313,837	(1,920,087)	2,334,901
Segment Result	(6,060,223)	98,243	(338,571)	(6,300,551)
Unallocated expenses				(2,955,289)
Result from operating activities				(9,255,840)
Finance costs				(34,167)
Loss before income tax				(9,290,007)
Income tax benefit				73,687
Loss after income tax				(9,216,320)
Segment assets	13,839,397	340,364	-	14,179,761
Unallocated assets				9,134,471
Total assets				23,314,232
Segment liabilities	2,015,006	497,179	-	2,512,185
Unallocated liabilities				(237,687)
Total liabilities				2,274,498
Capital expenditure	2,151,726	-	-	2,151,726
Depreciation and amortisation	726,003	-	363,359	1,089,362
Impairment expense	-	-	-	-

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

	Eden Innovations LLC	Eden Innovations India Pvt Ltd	Eliminations	Consolidated Entity
	$	$	$	$
2018				
External sales	1,204,298	113,662	-	1,317,960
Internal sales	1,416,928	-	(1,416,928)	-
Total segment revenue	2,621,226	113,662	(1,416,928)	1,317,960
Segment Result	(8,166,794)	(14,455)	(217,913)	(8,399,162)
Unallocated expenses				(2,583,296)
Result from operating activities				(10,982,458)
Finance costs				(24,572)
Loss before income tax				(11,007,030)
Income tax benefit				182,323
Loss after income tax				(10,824,707)
Segment assets	11,969,698	241,236	-	12,210,934
Unallocated assets				7,921,328
Total assets				20,132,262
Segment liabilities	2,105,846	605,224	(569,468)	2,141,602
Unallocated liabilities				229,091
Total liabilities				2,370,693
Capital expenditure	608,390	-	-	608,390
Depreciation and amortisation	679,858	-	343,486	1,023,344
Impairment expense	-	-	-	17,437

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

NOTE 25: FINANCIAL INSTRUMENTS

a. Financial Risk Exposures and Management

The main risks the company is exposed to through its financial instruments are liquidity risk and credit risk.

i. Liquidity Risk

The Group manages liquidity risk by monitoring forecast cash flows and ensuring that adequate funding is maintained.

The remaining contractual maturities of the Group financial liabilities are:

	2019 $	2018 $
12 months or less	1,459,553	1,279,697
1 year or more	772,355	984,296
Total	2,231,908	2,263,993

ii. Credit risk

Credit risk refers to the risk that the counterparty will default on its contractual obligations resulting in a financial loss to the company. The Group has adopted a policy of only dealing with credit worthy counterparties and obtaining sufficient collateral or other security where appropriate, as a means of mitigating the risk of financial loss from defaults.

The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date to recognised financial assets, is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the balance sheet and notes to the financial statements.

The Group does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered into by the company.

iii. Foreign currency risk

The Group is exposed to fluctuations in foreign currencies arising from the sale and purchase of goods and services in currencies other than the companies' functional currency. The risk is measure using sensitivity analysis and cash flow forecasting. At 30 June 2019, the effect on the loss and equity as a result of a 10% increase in the exchange rates, with all other variables remaining constant would be an decrease in loss by $640,000 (2018: decrease of loss of $800,000) and a increase in equity by $600,000 (2018: $300,000). A 10% decrease in the exchange rates would result in an equal and opposite impact on the loss after tax and equity.

iv. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The group's minimal exposure to interest rate risk, the only asset / liability affected by changes in market interest rates is Cash and cash equivalents.

b. Financial Instruments

Net Fair Values

The aggregate net fair values of financial assets and financial liabilities, at the balance date, are approximated by their carrying values.

NOTE 26: COMPANY DETAILS

The registered office of the company is:
Eden Innovations Ltd
Level 15
197 St Georges Terrace
Perth Western Australia 6000

The principal place of business is:
Eden Innovations Ltd
Level 15
197 St Georges Terrace
Perth Western Australia 6000

DIRECTORS' DECLARATION

In the opinion of the directors of Eden Innovations Ltd:

a. the financial statements and notes set out on pages 20 to 38, and the Remuneration disclosures that are contained in pages 15 to 17 of the Remuneration Report in the Directors' Report, are in accordance with the Corporations Act 2001, including:

   (i) giving a true and fair view of the Group's financial position as at 30 June 2019 and of its performance, for the financial year ended on that date; and

   (ii) complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Regulations 2001; and

   (iii) complying with International Financial Reporting Standards as disclosed in Note 1.

b. the remuneration disclosures that are contained in pages 15 to 17 of the Remuneration Report in the Directors' Report comply with Australian Accounting Standard AASB 124 Related Party Disclosures and

c. there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the Executive Chairman and Chief Financial Officer for the financial year ended 30 June 2019.

This declaration is made in accordance with a resolution of the Board of Directors.

____

Gregory H Solomon

Executive Chairman

Dated this 20th day of September 2019

Nexia Australia

Independent Auditor's Report to the Members of Eden Innovations Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Eden Innovations Ltd (the Company and its subsidiaries (the Group)), which comprises the consolidated statement of financial position as at 30 June 2019, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

(i) giving a true and fair view of the Group's financial position as at 30 June 2019 and of its performance for the year then ended; and

(ii) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty relating to going concern

Without modifying our opinion, we draw attention to Note 1 of the Financial Report, which indicates that the Group will require further funding in the next twelve months from the date of this report to fund its planned operating costs. These conditions, along with other matters as set forth in Note 1, indicate the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the Material Uncertainty Related to Going Concern section, we have determined the matter described below to be the key audit matter to be communicated in our report.

Nexia Perth
Audit Services Pty Ltd
ACN 145 447 105
Level 3, 88 William Street
Perth WA 6000
GPO Box 2570, Perth WA 6001
p +61 8 9463 2463
f +61 8 9463 2499
e audit@nexiaperth.com.au
w nexia.com.au

Key audit matter	How our audit addressed the key audit matter
CGU impairment assessment As at 30 June 2019 the Group's EdenCrete® and Optiblend® cash generating units (CGUs) comprised property plant and equipment (PPE) and Intangible assets. The carrying values of PPE and Intangible assets as at 30 June 2019 were, respectively, $12,463,621 (2018: $10,690,384) and $6,524,192 (2018: $4,907,542). Impairment was assessed by the Group at the CGU level by considering if impairment indicators were present. Management determined that there were no such indicators of impairment. The impairment assessment for the CGUs is a key audit matter due to: • the significance of the PPE and Intangible assets balances to the statement of financial position; and • the judgement involved in the impairment indicator assessment due to the need to make estimates about future events and other circumstances.	We performed the following procedures, among others, to evaluate the Group's impairment assessment: • assessed management's determination of the Group's CGUs based on our understanding of the nature of the Group's business and the economic environment in which the segments operate. We also analysed the internal reporting of the Group to assess how earning streams are monitored and reported; • compared actual sales performance for the year to sales of the preceding year; • enquired of management and inspected a selection of Board of Directors' meeting minutes to assess whether there were any: – observable indications that the asset values have declined during the year significantly more than would be expected as a result of the passage of time or normal use; – significant changes with an adverse effect on the entity that have taken place during the year, or will take place in the near future, in the technological, market, economic or legal environment in which the entity operates or in the market to which an asset is dedicated; or – significant changes with an adverse effect on the entity during the year, or any are expected to take place in the near future, in the extent to which, or manner in which, an asset is used or is expected to be used. • We also considered whether: – movements in market interest rates or other market rates of return on investments during the year are likely to affect the discount rate used in calculating an asset's value in use and decrease the asset's recoverable amount materially; – there was evidence of obsolescence or physical damage of assets comprising the CGUs; and – the market capitalisation of the Group was significantly lower than Eden Innovation's net assets at balance date.

Other information

The directors are responsible for the other information. The other information comprises the information in Eden Innovations Limited's annual report for the year ended 30 June 2019, but does not include the consolidated financial report and the auditor's report thereon.

Our opinion on the consolidated financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Directors' responsibility for the financial report

The directors of the Company are responsible for the preparation of the consolidated financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the entity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibility for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at The Australian Auditing and Assurance Standards Board website at: www.auasb.gov.au/auditors_responsibilities/ar2.pdf. This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 18 to 19 of the Directors' Report for the year ended 30 June 2019.

In our opinion, the Remuneration Report of Eden Innovations Limited for the year ended 30 June 2019, complies with Section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with Section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

NPAS

Nexia Perth Audit Services Pty Ltd

M. Janse Van Nieuwenhuizen | Director

Perth
20 September 2019

ADDITIONAL INFORMATION FOR LISTED PUBLIC COMPANIES

The following additional information is required by the Australian Securities Exchange Ltd.

1. Shareholding as at 6 September 2019

a. Distribution of Shareholders

Category (size of holding)	Number Ordinary
1 – 1,000	232
1,001 – 5,000	884
5,001 – 10,000	926
10,001 – 100,000	3,496
100,001 – and over	1,668
	7,206

b. The number of shareholdings held in less than marketable parcels is 1,737.

c. The names of the substantial shareholders listed in the holding company's register as at 6 September 2018 are:

Shareholder	Number Ordinary
Noble Energy Pty Ltd	624,634,707

d. Voting Rights

The voting rights attached to each class of equity security are as follows:

Ordinary shares - Each ordinary share is entitled to one vote when a poll is called, otherwise each member present at a meeting or by proxy has one vote on a show of hands.

e. 20 Largest Shareholders — Ordinary Shares

	Name	Number of Shares	% Issued Capital
1.	Noble Energy Pty Ltd	579,868,477	33.64%
2.	Noble Energy Pty Ltd	44,766,230	2.60%
3.	Arkenstone Pty Ltd <G H Solomon Family Inv A/c>	33,986,707	1.97%
4.	Citicorp Nominees Pty Ltd	29,145,903	1.69%
5.	March Bells Pty Ltd	28,730,343	1.67%
6.	Mr & Mrs Rogerson & Miss C Rogerson <The Rogerson Super Fund A/c>	27,138,937	1.57%
7.	Kalsie Holdings Pty Ltd <Iyer Superfund A/c>	17,730,610	1.03%
8.	Mr Wayne Kearney & Mrs Robyn Kearney <Kearney Super A/c>	12,760,313	0.74%
9.	J P Morgan Nominees Australia Limited	10,336,187	0.60%
10.	HSBC Custody Nominees (Australia) Limited	9,777,745	0.57%
11.	Mr Douglas Solomon	9,685,942	0.56%
12.	Mr Gregory Solomon	8,595,007	0.50%
13.	Miss Michelle Hawksley <MHawksley Family A/c>	8,041,316	0.47%
14.	BNP Paribas Noms Pty Ltd	7,122,953	0.41%
15.	Paddocks Superannuation Pty Ltd <Paddocks Super Fund A/c>	7,000,000	0.41%
16.	Mr Norman Maher	6,486,864	0.38%
17.	Mr Evan Clucas & Ms Leanne Weston <Kuranga Nursery Super A/c>	6,300,000	0.36%
18.	Mr Stephen Carter	6,058,135	0.35%
19.	Mr Boris Duka & Mrs Elizabeth Ann Duka	6,050,000	0.35%
20.	Mr John Geelan <Edward Sugar Family A/c>	6,000,000	0.35%
		865,581,669	50.22%

ADDITIONAL INFORMATION FOR LISTED PUBLIC COMPANIES

e. 20 Largest Optionholders — EDEOB

	Name	Number of Options	% of Issued
1.	Noble Energy Pty Ltd	14,814,815	21.26%
2.	Ultimate Site Development Pty Ltd	3,148,490	4.52%
3.	Mr Julian Merse	3,012,804	4.32%
4.	Mr John Geelan <Edward Sugar Family A/c>	3,000,000	4.31%
5.	Mr Brett Gage	2,720,000	3.90%
6.	Mr John Jarvis <John Jarvis Family A/c>	2,048,416	2.94%
7.	Citicorp Nominees Pty Ltd	1,927,856	2.77%
8.	Arkenstone Pty Ltd <G H Solomon Family Inv A/c>	1,544,851	2.22%
9.	Elysian Islands Pty Ltd <Elysian Islands S/f A/c>	1,566,176	2.25%
10.	March Bells Pty Ltd	1,292,289	1.85%
11.	Mr & Mrs Rogerson & Miss C Rogerson <The Rogerson Super Fund A/c>	1,092,594	1.57%
12.	Ulysseus Super Pty Ltd <The Ulysseus S/F A/C>	1,073,821	1.54%
13.	Celtic Capital Pty Ltd <The Celtic Capital A/c>	1,019,824	1.46%
14.	SPO Equities Pty Ltd	1,000,000	1.43%
15.	Philip Elghanian	1,000,000	1.43%
16.	Ricardo Salmon & Leslie Salmon	925,927	1.33%
17.	National Nominees Limited	925,927	1.33%
18.	Mr Jorgen Hansen and Mrs Ellen-Gerda Hansen	800,000	1.15%
19.	Mr Brendan Sharp	727,750	1.04%
20.	Mr Eddie Sugar	650,000	0.93%
		44,291,540	63.55%

2. Unquoted Securities – Options as at 6 September 2019

Holder Name	Date of Expiry	Exercise Price	Number on issue	Number of holders
Employee Share Options	28 February 2020	$0.27	24,729,422	21
Employee Share Options	30 November 2020	$0.25	330,000	1
Various	1 June 2021	$0.07	6,000,000	3
Various	1 June 2021	$0.08	6,000,000	3
			37,059,422	28

3. Unquoted Securities – Performance rights as at 6 September 2019

Holder Name	Date of Expiry	Vesting	Number on issue	Number of holders
Employee Performance Rights	31 August 2021	US$6m Revenue	8,297,004	36
Employee Performance Rights	31 August 2022	US$12m Revenue	8,297,004	36
Employee Performance Rights	31 August 2023	US$24m Revenue	8,297,004	36
			24,891,012	36

eden

Innovations that work.™

www.edeninnovations.com